{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:04:24Z","timestamp":1790899464522,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"am","delay-in-days":276,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fsigenetics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Forensic Science International: Genetics"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.fsigen.2020.102433","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T11:25:35Z","timestamp":1606562735000},"page":"102433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Pitfalls and challenges associated with phenoconversion in forensic toxcicology"],"prefix":"10.1016","volume":"51","author":[{"given":"G.","family":"Drevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Briet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Abbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.fsigen.2020.102433_bib0005","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bcp.12441","article-title":"Addressing phenoconversion: the Achilles\u2019 heel of personalized medicine: impact of phenoconversion","volume":"79","author":"Shah","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.fsigen.2020.102433_bib0010","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2125.2012.04328.x","article-title":"Personalized medicine: is it a pharmacogenetic mirage?","volume":"74","author":"Shah","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.fsigen.2020.102433_bib0015","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2125.2006.02683.x","article-title":"HapMap, pharmacogenomics, and the goal of personalized prescribing","volume":"61","author":"O\u2019Shaughnessy","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.fsigen.2020.102433_bib0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/jat\/30.2.65","article-title":"Pharmacogenomics for the forensic toxicologist","volume":"30","author":"Kupiec","year":"2006","journal-title":"J. Anal. Toxicol."},{"issue":"1\u20133","key":"10.1016\/j.fsigen.2020.102433_bib0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.forsciint.2010.07.011","article-title":"Pharmacogenetics and forensic toxicology","volume":"203","author":"Musshoff","year":"2010","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2020.102433_bib0030","first-page":"e1361","article-title":"Pharmacogenetics and the postmortem molecular autopsy","volume":"20","author":"Wendt","year":"2019","journal-title":"WIREs Forensic Sci."},{"key":"10.1016\/j.fsigen.2020.102433_bib0035","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"U.S. Food and Drug Administration","year":"2018"},{"issue":"2","key":"10.1016\/j.fsigen.2020.102433_bib0040","first-page":"219","article-title":"Accreditation of the toxicological screening: recommendations of the SFBC-SFTA group","volume":"77","author":"Guitton","year":"2019","journal-title":"Ann Biol Clin (Paris)."},{"key":"10.1016\/j.fsigen.2020.102433_bib0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1600-0447.1989.tb07176.x","article-title":"A review of the metabolism and pharmacokinetics of paroxetine in man","volume":"350","author":"Kaye","year":"1989","journal-title":"Acta Psychiatr Scan Suppl."},{"issue":"2","key":"10.1016\/j.fsigen.2020.102433_bib0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in european caucasians, asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.fsigen.2020.102433_bib0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13054-020-02915-5","article-title":"Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics","volume":"24","author":"Schulz","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.fsigen.2020.102433_bib0060","series-title":"Disposition of Toxic Drugs and Chemical in Man","author":"Baselt","year":"2017"},{"key":"10.1016\/j.fsigen.2020.102433_bib0065","series-title":"Clarke\u2019s Analytical Forensic Toxicology","author":"Negrusz","year":"2013"},{"issue":"1","key":"10.1016\/j.fsigen.2020.102433_bib0070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database","volume":"31","author":"Reis","year":"2009","journal-title":"Ther. Drug Monit."},{"issue":"1\u20133","key":"10.1016\/j.fsigen.2020.102433_bib0075","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.forsciint.2012.12.020","article-title":"A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine","volume":"226","author":"Jornil","year":"2013","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2020.102433_bib0080","series-title":"Principles of Clinical Pharmacology","article-title":"Clinical pharmacogenetics","author":"Flockhart","year":"2007"},{"issue":"3","key":"10.1016\/j.fsigen.2020.102433_bib0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/11586630-000000000-00000","article-title":"Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-Label, two-Period, parallel-group, crossover study","volume":"31","author":"Nichols","year":"2011","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"10.1016\/j.fsigen.2020.102433_bib0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2125.2007.02849.x","article-title":"Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases","volume":"64","author":"Howell","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.fsigen.2020.102433_bib0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/tpj.2014.50","article-title":"Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases","volume":"15","author":"Karlsson","year":"2015","journal-title":"Pharmacogenomics J."},{"issue":"5","key":"10.1016\/j.fsigen.2020.102433_bib0100","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/pgs.14.6","article-title":"How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping","volume":"15","author":"Verbeurgt","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.fsigen.2020.102433_bib0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0379-0738(03)00159-2","article-title":"Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood","volume":"135","author":"Levo","year":"2003","journal-title":"Forensic Sci. Int."},{"issue":"5","key":"10.1016\/j.fsigen.2020.102433_bib0110","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/jat\/bkz008","article-title":"Postmortem CYP2D6 genotyping and copy number determinations using DNA extracted from archived FTA bloodstains","volume":"43","author":"Melis","year":"2019","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.fsigen.2020.102433_bib0115","unstructured":"PharmGKB. https:\/\/www.pharmgkb.org\/."},{"issue":"7","key":"10.1016\/j.fsigen.2020.102433_bib0120","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.mpmed.2016.04.015","article-title":"Drug interactions","volume":"44","author":"Kennedy","year":"2016","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.fsigen.2020.102433_bib0125","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/tpj.2014.6","article-title":"Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia","volume":"14","author":"Suzuki","year":"2014","journal-title":"Pharmacogenomics J."},{"issue":"3","key":"10.1016\/j.fsigen.2020.102433_bib0130","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1124\/dmd.109.030551","article-title":"Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their Importance for human paroxetine metabolism using a population-based simulator","volume":"38","author":"Jornil","year":"2018","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.fsigen.2020.102433_bib0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.64719\/pb.4345","article-title":"Paroxetine \u2013 the antidepressant from hell? Probably not, but caution required","volume":"46","author":"Nevels","year":"2016","journal-title":"Psychopharmacoll Bull."},{"key":"10.1016\/j.fsigen.2020.102433_bib0140","unstructured":"DDI Predictor. https:\/\/www.ddi-predictor.org\/."},{"issue":"1","key":"10.1016\/j.fsigen.2020.102433_bib0145","first-page":"5","article-title":"CYP450 genotyping and cumulative drug\u2013gene interactions: an update for precision medicine","volume":"13","author":"Thirumaran","year":"2016","journal-title":"Med. Perspekt."},{"issue":"2","key":"10.1016\/j.fsigen.2020.102433_bib0150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ccr3.2604","article-title":"Precision medication: an illustrative case series guiding the clinical application of multi\u2010drug interactions and pharmacogenomics","volume":"8","author":"Bain","year":"2020","journal-title":"Clin. Case Rep."},{"issue":"3","key":"10.1016\/j.fsigen.2020.102433_bib0155","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/dmd.114.061093","article-title":"Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine","volume":"43","author":"Shah","year":"2015","journal-title":"Drug Metab. Dispos."}],"container-title":["Forensic Science International: Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1872497320302052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1872497320302052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:03:28Z","timestamp":1761735808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1872497320302052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":31,"alternative-id":["S1872497320302052"],"URL":"https:\/\/doi.org\/10.1016\/j.fsigen.2020.102433","relation":{},"ISSN":["1872-4973"],"issn-type":[{"value":"1872-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pitfalls and challenges associated with phenoconversion in forensic toxcicology","name":"articletitle","label":"Article Title"},{"value":"Forensic Science International: Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fsigen.2020.102433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102433"}}